High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: The ZEBRAS study

Journal of Clinical Psychopharmacology

Volumn 33, Issue 4, 2013, Pages 485-490

  Goff, Donald C ^a   McEvoy, Joseph P ^b   Citrome, Leslie ^c   Mech, Arnold W ^d   Bustillo, Juan R ^e   Gil, Roberto ^f   Buckley, Peter ^g   Manschreck, Theo C ^h   Achtyes, Eric D ⁱ   Macklin, Eric A ^j  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b John Umstead Hospital   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

^d Analytical Mechanics Associates   (United States)

^e UNIVERSITY OF NEW MEXICO   (United States)

^f NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^g MEDICAL COLLEGE OF GEORGIA   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ MICHIGAN STATE UNIVERSITY   (United States)

^j MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

high dose ziprasidone; residual symptoms; schizophrenia

Indexed keywords

PLACEBO; ZIPRASIDONE;

ADULT; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG MEGADOSE; ELECTROCARDIOGRAM; FEMALE; HEART RATE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; OUTPATIENT; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTIPSYCHOTIC AGENTS; BLOOD PRESSURE; FEMALE; HUMANS; LONG QT SYNDROME; MALE; MIDDLE AGED; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; THIAZOLES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84879842516     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182977308     Document Type: Article

References (22)

1. Strom BL, Eng SM, Faich G, et al. Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). Am J Psychiatry. 2011;168(2):193-201.
2. Citrome L. Drug safety evaluation of ziprasidone. Expert Opin Safety. 2011;10(3):437-448.
3. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223.
4. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol. 2004;24(2):192-208.
5. Citrome L, Jaffe A, Levine J. How dosing of ziprasidone in a state hospital system differs from product labeling. J Clin Psychiatry. 2009;70(7):975-982.
6. Deutschman DA, Deutschman DH, eds. High-Dose Ziprasidone: Effectiveness and Tolerability in Clinical Practice. Puerto Rico: Am College Neuropsychopharmacology; 2003.
7. Goodnick PJ. Higher than Physician's Desk Reference (US) doses on atypical antipsychotics. Expert Opin Drug Saf. 2005;4(4):653-668.
8. Bench CJ, Lammertsma AA, Dolan RJ, et al. Dose dependent occupancy of central dopamine D2 receptors by the novel neuroleptic CP-88,059-1: a study using positron emission tomography and 11C-raclopride. Psychopharmacol. 1993;112:308-314.
9. Goff D, Posever T, Herz L, et al. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol. 1998;18:296-304.
10. Daniel DG, Zimbroff DL, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacol. 1999;20:491-505.
11. Keck P Jr. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacol. 1998;140(2):173-184.
12. Komossa K, Rummel-Kluge C, Hunger H, et al. Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2009(4):CD006627.
13. Citrome L, Yang R, Glue P, et al. Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trials. Schizophr Res. 2009;111(1-3):39-45.
14. Mamo D, Kapur S, Shammi CM, et al. A PET study of dopamine D(2) and serotonin 5-HT(2) receptor occupancy in patients With schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry. 2004;161(5):818-825.
15. Gandelman K, Alderman JA, Glue P, et al. The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial. J Clin Psychiatry. 2009;70(1):58-62.
16. Obermeier M, Mayr A, Schennach-Wolff R, et al. Should the PANSS be rescaled? Schizophr Bull. 2010;36(3):455-460.
17. Miceli JJ, Glue P, Alderman J, et al. The effect of food on the absorption of oral ziprasidone. Psychopharmacol Bull. 2007;40(3):58-68.
18. Miceli JJ, Tensfeldt TG, Shiovitz T, et al. Effects of oral ziprasidone and oral haloperidol on QTc interval in patients with schizophrenia or schizoaffective disorder. Pharmacotherapy. 2010;30(2):127-135.
19. Miceli JJ, Tensfeldt TG, Shiovitz T, et al. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder. Clin Ther. 2010;32(3):472-491.
20. Hamelin BA, Allard S, Laplante L, et al. The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone. Pharmacotherapy. 1998;18(1):9-15.
21. Wessels AM, Bies RR, Pollock BG, et al. Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study. J Clin Pharmacol. 2011;51(11):1587-1591.
22. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360(3):225-235.